Koers Stereotaxis Inc Nasdaq
Aandelen
US85916J4094
Geavanceerde medische apparatuur & technologie
Omzet 2024 * | 30,4 mln. 28,08 mln. | Omzet 2025 * | 43,6 mln. 40,27 mln. | Marktkapitalisatie | 147 mln. 136 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -18 mln. -16,63 mln. | Nettowinst (verlies) 2025 * | -15 mln. -13,86 mln. | EV/omzet 2024 * | 4,84 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 3,37 x |
K/w-verhouding 2024 * |
-7,46
x | K/w-verhouding 2025 * |
-8,14
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 84,16% |
Recentste transcriptie over Stereotaxis Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Fischel
CEO | Chief Executive Officer | 57 | 29-09-16 |
Kimberly Peery
DFI | Director of Finance/CFO | 55 | 01-01-03 |
Laura Garth
LAW | General Counsel | - | 01-01-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Messey
BRD | Director/Board Member | 78 | 01-05-05 |
David Fischel
CEO | Chief Executive Officer | 57 | 29-09-16 |
Nathan Fischel
BRD | Director/Board Member | 68 | 03-02-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,91% | 204 mld. | |
+3,74% | 178 mld. | |
+28,89% | 154 mld. | |
+31,66% | 112 mld. | |
+1,22% | 64,32 mld. | |
+19,45% | 54,88 mld. | |
-2,27% | 47,24 mld. | |
-9,28% | 36,8 mld. | |
-0,10% | 35,26 mld. |